BRUKINSA - A Powerful Choice in R/R mcl

24-hour inhibition of BTK was maintained at 100% in PBMCs and 94% to 100% in lymph nodes when taken at the recommended total daily dose of 320 mg. The clinical significance of 100% inhibition has not been established.1,2

THE BTK INHIBITOR
FOR R/R mcl DEMONSTRATED
TO PROVIDE COMPLETE
AND SUSTAINED INHIBITION1,2

NCCN
Category 2A
Preferred
Zanubrutinib (BRUKINSA®) is included as a category 2A preferred treatment option for second-line and subsequent therapy for MCL in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)3

POWERFUL, CONSISTENT RESPONSES

Initial analysis (18 months)1,4

84% of patients responded to BRUKINSA across both studies.1

Study 206
| PET-BASED
(N=86)
84
%
ORR
59
%
CR
Study 003 (MCL)
| CT-BASED
(N=32)
84
%
ORR
22
%
CR

Median follow-up time was 18.4 months for Study 206 and 18.8 months for Study 003.4



Long-Term analysis (35 months)5

84% of patients responded to BRUKINSA
in the long-term analysis.5

Study 206
| PET-BASED
(N=86)
84
%
ORR
78
%
CR

Median follow-up time was 35.3 months for Study 206.5

The efficacy of BRUKINSA was assessed in 2 clinical trials that included a total of 118 adult patients with MCL who received at least 1 prior therapy. Study BGB-3111-206 (Study 206): N=86, Phase 2, open-label, multicenter, single-arm trial; PET scans were required for response assessment. Study BGB-3111-AU-003 (Study 003): N=32, Phase 1/2, open-label, multicenter, single-arm trial; PET scans were not required for response assessment and the majority of patients were assessed mostly using CT scans.


BTK=Bruton’s tyrosine kinase; CI=confidence interval; CR=complete response; CT=computed tomography; IRC=independent review committee; NCCN=National Comprehensive Cancer Network; ORR=overall response rate; PBMCs=peripheral blood mononuclear cells; PET=positron emission tomography.

Personalized patient support
dedicated to helping patients

A personalized and comprehensive support program designed
to help guide and assist patients, caregivers, and practices.

Simplifying
Access
Educating
Patients
Securing
Support

Healthcare professional resources

Find tools and education to help your practice

Complete
BTK inhibition
Brukinsa Difference
Established
Safety Profile
Safety
Flexible
Dosing
Dosing